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We report an inhibitor of the homodimeric protein-protein interaction of the BCL6 
oncoprotein, identified from a genetically encoded SICLOPPS library of 3.2 million 
cyclic hexpeptides in combination with a bacterial reverse two-hybrid system. This 
cyclic peptide is shown to bind the BTB domain of BCL6, disrupts its 
homodimerization, and subsequent binding of the SMRT2 corepressor peptide. 
 
Introduction 
The B-cell lymphoma 6 (BCL6) transcription factor[1, 2] is a master regulator of the 
germinal centre, which acts by repressing a plethora of critical genes involved in the 
DNA damage response and cell cycle checkpoints.[3-6] Aberrant expression of BCL6 
is associated with the uncontrollable growth and proliferation of B-cells, driving the 
malignant diffuse large B-cell lymphoma (DLBCL) phenotype. The BCL6 proto-
oncogene encodes a 706 amino acid (79 kDa) zinc finger transcription factor, which is 
comprised of three distinct domains.[2] The N-terminal bric-a-brac, tramtrack and 
broad-complex (BTB) domain (residues 5-129) plays a fundamental role in the activity 
of BCL6 by mediating obligate homodimerization and subsequently recruiting co-
repressor molecules that repress target genes in multi-protein histone deacetylase 
complexes.[7] Thus BTB homodimerization is an absolute requirement and critical for 
BCL6 repressor functions; upon dimerization, each BTB monomer forms a tight 
intertwined butterfly like homodimer in which approximately a quarter of the monomer 
surface is masked upon dimer formation.[8] The only prerequisite for the correct folding 
of the BTB domain of BCL6 is homodimerization, and the interaction is obligate in 
nature, with an unmeasurable affinity.[9] Dimerization generates a symmetrical binding 
site at the interface of the two domains known as the lateral groove. This groove creates 
a docking site that allows specific binding of three co-repressor proteins, nuclear-
receptor co-repressor 1 (NCoR1), and silencing mediator for retinoid and thyroid 
receptor (SMRT) and BCL6-co-repressor (BCoR) to bind exclusively.[10-12] Over the 
past decade, BTB-SMRT/BCoR heterodimerization has been extensively explored and 
a number of inhibitors of this Protein-protein interaction (PPI) have been reported.[13-
17] There are currently no BTB inhibitors in the clinic, and there are no molecules 
reported that inhibit BTB homodimerization. Given our prior successes with a 
genetically encoded high-throughput screening platform,[18-21] we sought to probe the 




Constructing the BTB RTHS and SICLOPPS screening 
We began by constructing a bacterial reverse two-hybrid system (RTHS),[22] where 
survival and growth of the host E. coli would be dependent on inhibition of BTB 
homodimerization (Figure 1a). In this RTHS, the targeted protein is expressed as a 
fusion with the 434 repressor protein; homodimerization of the targeted protein (BTB in 
this case) results in formation of a functional 434 repressor that binds to engineered 
chromosomal operators, and prevents reporter-gene expression (Figure 1a). Disruption 
of the target PPI will also disrupt the 434 repressor complex, leading to reporter gene 
expression and growth of the host strain on selective media (Figure 1a). Performance 
of the constructed BTB RTHS was initially assessed by the function of protein encoded 
by the LacZ reporter gene (ß-galactosidase) using an o-nitrophneyl-ß-D-
galactopyranoside (ONPG) assay. In line with repressor formation, an IPTG-dependent 
reduction in LacZ activity was observed in this assay (Figure 1b). We further assessed 
the BTB RTHS by ten-fold serial dilution drop-spotting on selective media; formation of 
a functional repressor would be expected to lead to cell death on selective media (due 
to the absence of expression of the first and second reporter genes HIS3 and KanR). 
We observed significant inhibition of growth at 5 µM IPTG (Figure 1c), confirming the 
formation of a functional repressor. We next used this BTB RTHS in combination with 
a 3.2 million member SICLOPPS CX5 cyclic peptide library (where X = any 
proteinogenic amino acid); a cyclic peptide inhibitor of BTB homodimerization would 
also disrupt the 434 repressor, and consequently result in survival of a bacterial host 
on selective media (Figure 1a). After transformation with the SICLOPPS plasmid 
library, approximately 107 E. coli transformants were plated onto selective media plates 
supplemented with L-arabinose (inducer of cyclic peptide production). Around 4000 
surviving colonies were observed, and these were individually assessed for their ability 
to disrupt the BTB homodimer using the BTB RTHS.[23] Activity of the selected 
peptides were ranked by drop spotting, with a single peptide illustrating significantly 
more potent activity (Figure 1C, bottom row). The identity of this peptide was 
deconvoluted as cyclo-CIYYCV by isolating and sequencing the parent SICLOPPS 
plasmid. This cyclic peptide was subsequently synthesized by solid-phase peptide 
synthesis for use in the following in vitro assays. 
 
 
Figure 1: Screening a SICLOPPS library with the BTB RTHS. (a) BTB is expressed as a fusion with 
the 434 bacteriophage repressor protein. Homodimerization of BTB reconstitutes the repressor, 
preventing transcription of three reporter genes. An inhibitor of BTB homodimerization will also disrupt 
repressor formation, enabling expression of the reporter genes, leading to survival and growth of the 
BTB RTHS on selective media. (b) ONPG assay shows a loss of β-galactosidase activity (LacZ reporter 
gene product) in response to an increase in IPTG concentrations, indicating formation of a functional 
repressor. Data presented as Mean  SEM, n=3. (c) Drop-spotting 10-fold serial dilutions (2.5 μL of 10n 
cells/mL) of the BTB RTHS. In the absence of IPTG and arabinose, full growth is observed, whereas in 
the presence of 5 μM IPTG growth of the RTHS is repressed by ~4 spots. In the presence of 3.25 μM 
arabinose (inducing SICLOPPS) and 5 μM IPTG growth of the RTHS is restored, due to disruption of 
the BTB PPI. 
 
Assessing the binding of cyclo-CIYYCV to BTB in vitro 
The ability of cyclo-CIYYCV (figure 2a) to bind to the BTB homodimer was probed in 
vitro using two recombinant proteins. The first was a BTB5-129 wild-type (WT) protein 
that required a non-cleavable glutathione S-transferase (GST) tag to enhance its 
solubility. The second variant of the BTB protein was a previously reported triple 
cysteine mutant C8Q, C67R and C84N (3CysMut from herein); these mutations have 
been shown to significantly enhance solubility and prevented aggregation when 
expressed with a His6 tag.[9, 24, 25] The GST-BTB WT and 3CysMut proteins were 
used in parallel to characterize the identified inhibitor, to ensure that neither the GST 
tag, nor the 3 cysteine mutations were significantly altering the native state of the 
protein. Given that our inhibitor contains two cysteines, it may also be forming disulfide 
bonds with the protein. We initially quantified the binding affinity of cyclo-CIYYCV to 
BTB by microscale thermophoresis (MST). We observed an apparent KD value of 142 
± 25 µM when using GST-BTB (figure 2b) and 50 ± 11 µM when using 3CysMut BTB 
(Figure 2c). The difference observed in these values is likely a consequence of steric 
hindrance by the large GST affinity tag partially blocking the binding site of cyclo-
CIYYCV on BTB. We next probed the effect of cyclo-CIYYCV on protein stability by a 
thermal shift assay; the resulting data suggests that cyclo-CIYYCV increasingly 
stabilizes BTB with a dose-dependent increase in melting temperature observed for 
both GST-BTB (Supplemental Figure 1) and 3CysMut BTB (Figure 2d). We therefore 
sought to assess the role of potential disulfide bonds in the activity of our inhibitor. 
 
 
Figure 2: in vitro analysis of the binding of cyclo-CIYYCV to BTB. (a) Structure of cyclo-CIYYCV. 
(b) cyclo-CIYYCV binds to GST-BTB with a KD of 142 ± 25 µM by MST. (c) cyclo-CIYYCV binds to 
3CysMut BTB with a KD of 50 ± 11 µM by MST. (d) cyclo-CIYYCV causes a dose dependent change in 
the melting temperature of 3cysMut BTB. (e) GST-BTB binds to fluorescently labelled SMRT2 peptide 
in the presence of 2.5 mM DTT, with a KD of 1.0 ± 0.03 µM by MST. (f) GST-BTB binds to fluorescently 
labelled SMRT2 peptide with a KD of 0.3 ± 0.08 µM by MST. All data presented as Mean  SEM, n=3. 
 
Probing the requirement of disulfide bonds for cyclo-CIYYCV activity 
To investigate this, the binding of our cyclic peptide inhibitor to BTB was assessed by 
MST in the presence of 2.5 mM DTT, which would be expected to disrupt disulfide 
bonds. We observed loss of all activity for cyclo-CIYYCV, against both the WT and 
3CysMut protein (Supplemental Figure 2). To determine whether this observed loss of 
activity was due to the DTT-mediated unfolding of BTB, we assessed the binding of the 
SMRT2 peptide to this protein in the presence and absence of DTT. It is well 
established that the SMRT2 corepressor peptide binds to the lateral groove of the BTB 
homodimer and cannot bind if the protein is misfolded, unfolded or in a monomeric 
state.[9] We synthesized a fluorescent derivative of the SMRT2 peptide 
(carboxyfluorescein-LVATVKEAGRSIWEIPR). This peptide was found to bind GST-
BTB in the presence of DTT with a KD of 1 ± 0.03 µM (Figure 2e) by MST. Repeating 
this experiment in the absence of DTT, we observed a KD of 0.3 ± 0.08 µM for the same 
interaction (Figure 2f). This observed lack of effect from DTT on the binding of SMRT2 
to GST-BTB indicates that DTT is unlikely to be affecting the tertiary and quaternary 
structure of BTB.  
To ascertain whether the loss of cyclo-CIYYCV binding to BTB in the presence of DTT 
was dependent on intramolecular disulfide interactions between the two cysteins of the 
cyclic peptide, an Ellman’s assay was performed, which may be used to determine the 
number of free cysteines in a molecule. We observed an absorbance approximately 
double that of a control containing one free cysteine residue (Supplemental Figure 3), 
indicating that in the absence of DTT and under assay conditions, both cysteine 
reisudes of cyclo-CIYYCV were in a reduced state. Together, this data indicates that 
the observed loss of activity associated with the presence of DTT is likely due to the 
disruption of disulfide interactions between the cyclic peptide and BTB. However, it is 
possible that despite the presence of DTT, an intramolecular disulfide bond persists in 
cyclo-CIYYCV and is required for its activity. One of the cysteins in such a species may 
still form a disulfide bond to BTB via disulfide shuffling. 
 
Disruption of BTB homodimerization by cyclo-CIYYCV in vitro 
We next used size exclusion chromatography (SEC) to assess the effect of cyclo-
CIYYCV on the BTB dimer to monomer equilibrium. The 3CysMut protein was used in 
this experiment to avoid false negatives with BTB-GST arising from GST 
homodimerization. We observed a small shift in the 3CysMut BTB protein elution 
volume (from 2.18 mL to 2.22 mL) in the presence of our cyclic peptide inhibitor. This 
corresponded to a potential 12 kDa shift towards monomeric BTB (Figure 3a), 
consistent with data from the BTB RTHS (Figure 1c) that cyclo-CIYYCV disrupts the 
BTB homodimer. We further sought to verify the effect of our inhibitor on the 
dimerization status of BTB using an indirect assay; the SMRT2 corepressor peptide is 
known to bind to the lateral groove formed at the interface of the BTB homodimer, thus 
a BTB homodimerization inhibitor would be expected to reduce the apparent affinity of 
this interaction. We therefore used a competitive MST assay to measure the affinity of 
SMRT2 for 3CysMut BTB in the presence and absence of cyclo-CIYYCV. We observed 
a KD of 25 ± 10 µM for SMRT2 binding to BTB in the absence of our cyclic peptide 
(Figure 3b), consistent with previously published data.[9, 13, 26] In line with our 
hypothesis, we observed a ~3-fold reduction in the affinity of this interaction in the 
presence of cyclo-CIYYCV (300 µM), with a KD of 81 ± 14 µM measured for SMRT2 
binding to BTB in the presence of our cyclic peptide (Figure 3c).  
 
 
Figure 3: Assessing the ability of cyclo-CIYYCV to disrupt BTB dimerization. (a) Size exclusion 
chromatography of 3CysMut BTB incubated in the presence and absence of cyclo-CIYYCV, the data 
shows BTB shifts towards monomer in the presence of the inhibitor. (b) 3CysMut BTB binds to the 
SMRT2 peptide with a KD of 25 ± 10 µM by MST. (c) 3CysMut BTB binds to the SMRT2 peptide in the 
presence of cyclo-CIYYCV (300µM) with a KD of 81 ± 14 µM by MST, a 3-fold reduction in affinity in the 
presence of the inhibitor. 
 
Identifying the critical residues of cyclo-CIYYCV by alanine scanning 
The residues of cyclo-CIYYCV that are critical for binding to BTB were identified by 
alanine scanning. We synthesized six derivatives of the parent cyclic peptide, each with 
a single amino acid replaced with alanine. The relative activity of each of these 
molecules (1 mM) was assessed by single-point MST; with a drop or loss of signal 
amplitude relative to the parent molecule, indicating reduced affinity or lack of binding. 
The data indicated that each of the two cysteines was critical for activity, with 
replacement of either with alanine resulting in loss of binding (Figure 4a). Surprisingly, 
only the second tyrosine was critical to activity of the cyclic peptide, whereas 
replacement of the first tyrosine only resulted in minor activity loss (Figure 4a). 
Replacement of either the isoleucine or valine with alanine also didn’t affect binding to 
BTB (Figure 4a). Overall 3 of the 6 amino acids in cyclo-CIYYCV were found to be 
essential for its activity (Figure 4b). This data provides further evidence for disulphide 
bonding playing an important role in the activity of this molecule.  
 
 Figure 4: The critical residues of cyclo-CIYYCV. (a) Comparing the effect of 1mM of cyclo-CIYYCV 
with its 6 alanine-scanning analogues on the MST signal of fluorescently labelled BTB protein. Binding 
affinity of each molecule for BTB correlates to signal amplitude (i.e. low signal = weaker binding). (b) 
The structure of cyclo-CIYYCV with residues critical for its activity highlighted in red. Residues whose 
replacement with alanine did not have a large effect on binding to BTB are highlighted in green.  
 
Conclusions 
Taken together, the above data demonstrates that cyclo-CIYYCV binds to BTB and 
disrupts its homodimerization. The disparity between the apparent affinity of BTB 
monomers for each other, versus the binding constant of our cyclic peptide to BTB, 
suggests either a non-reversible mechanism of inhibition, or targeting of an allosteric 
site. We observed that DTT abrogates the activity of this molecule, and our data 
suggests that this may be due to the disruption of an intermolecular disulphide bond 
between the inhibitor and BTB. It is interesting to note that the reducing intracellular 
environment of the E. coli host used in our screen is likely to disfavour disulphide bond 
formation, yet cyclo-CIYYCV was selected in this screen and disrupts BTB 
homodimerization in the RTHS. Regardless of its mechanism of action, the moderate 
potency of the identified inhibitor limits its further characterization (both in vitro and in 
cells), and there is a need to improve the potency of our inhibitor. This may be achieved 
by improving non-covalent affinity via incorporation of non-natural amino acids, as we 
have previously demonstrated for other peptides.[19, 27, 28] Alanine-scanning of the 
cyclic peptide identified the two cysteines and the second tyrosine as critical to the 
activity of our BTB inhibitor. These residues, particularly the tyrosine may be substituted 
with non-natural analogues, while one or both cysteines may be replaced with a 
cysteine-trapping residue such as an acrylamide. Thus, this first in class inhibitor, 
identified from a genetically encoded SICLOPPS library provides a good foundation for 
development of future BTB homodimerization inhibitors, which may serve as tools or 
lead molecules for the development of therapeutic agents targeted toward DLBCL. 
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